DuPont Pharmaceuticals' Teti Adds CEO To Title With Landgraf Resignation
Executive Summary
DuPont President-Pharmaceuticals Nicholas Teti will add Chief Executive Officer to his title with the resignation of Kurt Landgraf, effective May 15.
You may also be interested in...
Pharmacia North America Rx President Is Spiers; Hassan Adds Chairman Title
Pharmacia North American Pharmaceuticals President Mark Spiers will lead the company's search for a new head of U.S. sales.
DuPont Spinning Off Rx Business As Cozaar Profit-Share Trigger Nears
DuPont's handling of the profit-sharing agreement for Cozaar is a central consideration in the valuing of the company's planned prescription drug spin-off.
DuPont Spinning Off Rx Business As Cozaar Profit-Share Trigger Nears
DuPont's handling of the profit-sharing agreement for Cozaar is a central consideration in the valuing of the company's planned prescription drug spin-off.